Sequential positron emission tomography using [18F] fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6437-6443

  Couturier, Olivier ^a   Jerusalem, Guy ^c   N'Guyen, Jean Michel ^b   Hustinx, Roland ^c  

^a HÔTEL DIEU   (France)

^b CHU DE NANTES   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER RECURRENCE; CANCER THERAPY; CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESPONSE; HUMAN; IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33751301846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0383     Document Type: Article

References (24)

1. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28:351-8.
2. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228:220-7.
3. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-70.
4. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618-23.
5. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-5.
6. Jerusalem G, Hustinx R, Beguin Y, Fillet G. PET scan imaging in oncology. Eur J Cancer 2003;39:1525-34.
7. 18F-FDG PET. J Nucl Med 2005;46:1144-50.
8. 18F-FDG PET. J Nucl Med 2002; 43:1304-9.
9. Adam LE, Karp JS, Daube-Witherspoon ME, et al. Performance of a whole-body PET scanner using curve-plate NaI(TI) detectors. J Nucl Med 2001;42: 1821-30.
10. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82.
11. DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
13. Rostom AY, Powe J, Kandil A, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999;72:1064-8.
14. Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:5118-24.
15. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13: 1470-7.
16. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
17. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-88.
18. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
19. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-8.
20. 18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156-61; discussion 162-3.
21. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005;7: 307-11.
22. Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 2004;45:784-8.
23. Krak NC, Boellaard R, Hoekstra OS, et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005;32: 294-301.
24. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000;85: 613-8.